139 related articles for article (PubMed ID: 1394778)
1. Low seroconversion rates to measles vaccine among children in Nigeria.
Adu FD; Akinwolere OA; Tomori O; Uche LN
Bull World Health Organ; 1992; 70(4):457-60. PubMed ID: 1394778
[TBL] [Abstract][Full Text] [Related]
2. Measles outbreak in Ibadan: clinical, serological and virological identification of affected children in selected hospitals.
Adu FD; Ikusika A; Omotade O
J Infect; 1997 Nov; 35(3):241-5. PubMed ID: 9459395
[TBL] [Abstract][Full Text] [Related]
3. Child mortality following standard, medium or high titre measles immunization in West Africa.
Knudsen KM; Aaby P; Whittle H; Rowe M; Samb B; Simondon F; Sterne J; Fine P
Int J Epidemiol; 1996 Jun; 25(3):665-73. PubMed ID: 8671571
[TBL] [Abstract][Full Text] [Related]
4. Comparison of AIK-C measles vaccine in infants at 6 months with Schwarz vaccine at 9 months: a randomized controlled trial in Ghana.
Nkrumah FK; Osei-Kwasi M; Dunyo SK; Koram KA; Afari EA
Bull World Health Organ; 1998; 76(4):353-9. PubMed ID: 9803586
[TBL] [Abstract][Full Text] [Related]
5. Haemagglutination inhibition antibody levels one year after natural measles infection and vaccination.
Eghafona NO; Ahmad AA; Ezeokoli CD; Emejuaiwe SO
Microbios; 1991; 67(274):33-6. PubMed ID: 1758308
[TBL] [Abstract][Full Text] [Related]
6. [Efficacy evaluation of measles vaccine in fields].
Liu M
Zhonghua Liu Xing Bing Xue Za Zhi; 1991 Oct; 12(5):292-4. PubMed ID: 1782660
[TBL] [Abstract][Full Text] [Related]
7. Comparative efficacy of three measles vaccines in Indian children.
Banerjee K; Shaikh N; Phadke M; Bedekar SS; Rauta SK; Mehta JM
Indian J Public Health; 1998; 42(4):113-9. PubMed ID: 10389523
[TBL] [Abstract][Full Text] [Related]
8. [The development and duration of immunity in children vaccinated against measles with the Edmonston-Zagreb vaccine].
Borcić B; Smerdel S; Abu Eldan J; Kolić J; Ferdebar M; Kordić D; Mohacek N
Lijec Vjesn; 1989; 111(4-5):131-4. PubMed ID: 2770398
[TBL] [Abstract][Full Text] [Related]
9. [Studies on the persistence of immunity 14-15 years after vaccination with a live measles vaccine].
Zhonghua Yi Xue Za Zhi; 1989 Jul; 69(7):389-91. PubMed ID: 2598095
[No Abstract] [Full Text] [Related]
10. Immune response to Edmonston-Zagreb measles virus strain in monovalent and combined MMR vaccine.
Beck M; Smerdel S; Dedić I; Delimar N; Rajninger-Miholic M; Juzbasić M; Manhalter T; Vlatković R; Borcić B; Mihajić Z
Dev Biol Stand; 1986; 65():95-100. PubMed ID: 3556780
[TBL] [Abstract][Full Text] [Related]
11. Comparative study and evaluation of further attenuated, live measles vaccines alone and in combination with mumps and rubella vaccines.
Wegmann A; Glück R; Just M; Mischler R; Paroz P; Germanier R
Dev Biol Stand; 1986; 65():69-74. PubMed ID: 3556778
[TBL] [Abstract][Full Text] [Related]
12. The role of herd immunity in control of measles.
Black FL
Yale J Biol Med; 1982; 55(3-4):351-60. PubMed ID: 7180027
[TBL] [Abstract][Full Text] [Related]
13. Immune status following measles vaccination in infants and evaluation for the need of revaccination.
Dutta AK; Singhal PK; Khare S; Kumari S; Mathur R; Mullick DN
Indian Pediatr; 1989 Aug; 26(8):765-72. PubMed ID: 2620977
[TBL] [Abstract][Full Text] [Related]
14. [The clinico-immunological evaluation of a bivalent vaccine against measles and rubella].
Schettini F; Manzionna MM; De Mattia D; Amendola F; Di Bitonto G
Minerva Pediatr; 1990 Dec; 42(12):531-6. PubMed ID: 2087226
[TBL] [Abstract][Full Text] [Related]
15. Duration of immunity following immunization with live measles vaccine: 15 years of observation in Zhejiang Province, China.
Dai B; Chen ZH; Liu QC; Wu T; Guo CY; Wang XZ; Fang HH; Xiang YZ
Bull World Health Organ; 1991; 69(4):415-23. PubMed ID: 1934235
[TBL] [Abstract][Full Text] [Related]
16. Field trial of combined yellow fever and measles vaccines among children in Nigeria.
Adu FD; Omotade OO; Oyedele OI; Ikusika O; Odemuyiwa SO; Onoja AL
East Afr Med J; 1996 Sep; 73(9):579-82. PubMed ID: 8991237
[TBL] [Abstract][Full Text] [Related]
17. Expanded programme on immunization (EPI). Safety of high titre measles vaccines.
Wkly Epidemiol Rec; 1992 Nov; 67(48):357-61. PubMed ID: 1449986
[TBL] [Abstract][Full Text] [Related]
18. Optimal age for vaccinating Nigerian children against measles. II. Seroconversion to measles vaccine in different age groups.
Ogunmekan DA; Harry TO
Trop Geogr Med; 1981 Dec; 33(4):379-82. PubMed ID: 7342385
[TBL] [Abstract][Full Text] [Related]
19. [Measurement of the in vitro immune response of live attenuated measles virus vaccine and antibody levels in 0 to 10-year-old children].
Unalan H; Ustaçelebi S
Mikrobiyol Bul; 1985 Oct; 19(4):218-28. PubMed ID: 3831724
[TBL] [Abstract][Full Text] [Related]
20. Serological survey of measles immunization with the Rimevax--RIT--vaccine in a Romanian district.
Ciufecu E; Dincă L; Serbănescu R; Dinculescu M; Găleşanu M
Arch Roum Pathol Exp Microbiol; 1980; 39(1):31-40. PubMed ID: 6996640
[No Abstract] [Full Text] [Related]
[Next] [New Search]
